Calciphylaxis (Calcific Uremic Arteriolopathy): ʻO nā Plaques Violaceous Retiform Plaques, ʻEleʻele Necrotic Eschars i nā maʻi Dialysis, a me Sodium Thiosulfate¶

ʻO Calciphylaxis, i koho ʻia ma ke ʻano he calcific uremic arteriolopathy (CUA) ke loaʻa ia i nā poʻe maʻi me ka maʻi kīkī hope loa, he maʻi hoʻopōʻino, hoʻoweliweli i ke ola ʻana o ka calcification vascular i hōʻike ʻia e calcification medial, subintimal fibrosis, a me ka occlusion thrombotic acute o nā dermal liʻiliʻi a me nā ʻāpana liʻiliʻi o ke anawaena60. ʻAʻole e like me ka maʻi atherosclerotic peripheral arterial maʻamau e hōʻemi i nā aʻa aʻa i kapa ʻia i loko o nā wāwae i ka haʻalele ʻana i nā puʻupuʻu pedal nāwaliwali a ʻaʻole ʻole paha, ua pā ka calciphylaxis i ka ʻupena arteriolar microscopic i hoʻokomo ʻia i loko o ** nā ʻiʻo momona subcutaneous waiwai nui i ka adipose ** (ka ʻōpū, panniculus, ʻūhā, ʻūhā, a me nā ʻūhā pinepine) e ʻike maopopo ʻia. I ka mea maʻi ma ka hemodialysis mau a i ʻole ka dialysis peritoneal, a i ka mea maʻi me ka hana renal maʻamau e lawe nei warfarin (non-uremic calciphylaxis), ka nalowale o nā mea hoʻopaneʻe calcification vascular maoli, ʻo ia hoʻi ** carboxylated Matrix Gla Protein (MGP)* a me ka hepatic fetuin-A, i hui pū ʻia me hyperphosphatemia, elevated calcium-phosphate, hypercalcemia, hypercalcemia. pacalcitol), nā mea hoʻopaʻa phosphate ma muli o ka calcium (calcium acetate, calcium carbonate), a me nā hoʻoheheʻe subcutaneous hou (insulin a i ʻole heparin) e hoʻoulu ai i ka hoʻololi phenotypic o nā ʻiʻo maʻemaʻe vascular i loko o nā iwi osteoblast-like cell. Ke pani ʻia ka lumen arteriolar calcified e kahi thrombus fibrin acute, ʻo ka ʻili a me ka momona e loaʻa i ka pōʻino. Ma ke kino, hoʻolaha ka calciphylaxis iā ia iho me excruciating, wela, 10-out-of-10 ischemic ʻeha ʻili e hele pinepine ana ma mua o ka necrosis ʻili i ʻike ʻia i nā lā, e ulu wikiwiki ana mai mottled violaceous retiform (like net) purpura and rock-hard, woody subcutaneous nodules ( i loko o ka ** ʻeleʻele ʻeleʻele, ** ʻeleʻele ʻeleʻele (**) hoʻopuni ʻia e nā palena ʻinoʻino. Ma muli o ka noho pono ʻana o nā eschars calciphylaxis ulcerated ma luna o ka momona devitalized, hiki i ka hoʻouka ʻana i ka maʻi bacteria lua i ka fulminant injury sepsis, e hoʻokau ana i ka helu make o hoʻokahi makahiki o 50 a 80 pakeneka. Inā hoʻomohala ka mea maʻi dialysis a mea hoʻohana paha i ka warfarin i nā plaque e like me ka ʻupena poni ʻehaʻeha, nā nodules subcutaneous lāʻau, a i ʻole nā maʻi ʻeleʻele necrotic ʻili, e kelepona i kou wahi. helu pilikia a i ʻole e hele koke i kahi keʻena pilikia. E nānā pū i kā mākou alakaʻi kaikaina ma ʻO ka loaʻa ʻana o ka maʻi maʻi maʻi AV fistula e hoʻoweliweli i ke koko a me ka hyperkalemia dialysis i hala, erysipelas vs necrotizing fasciitis vs stasis dermatitis triage, a sepsis a me ka ʻike haʻalulu septic.

ʻO kāu mau mea nui e pili ana i ka ulia pōpilikia ʻo ka ** hoʻopau koke i nā accelerators calcification a pau , hoʻōki i ka ** warfarin (e hoʻololi i kahi anticoagulant waha pololei e like me apixaban a i ʻole heparin haʻahaʻa-molecular-weight ma hope o ka loiloi loea, ʻoiai e hāʻawi ana i ka Vitamin K1 intravenous e hoʻāla hou i ka Matrix Gla Protein), e hoʻōki ** i nā calcium binder-containing a pau. sevelamer a i ʻole lanthanum), a me ka hoʻokuʻu ʻana i ** mau mea hoʻohālikelike Vitamin D ikaika (e hoʻololi i ka calcimimetics e like me cinacalcet a i ʻole etelcalcetide inā loaʻa ka hyperparathyroidism lua). I ka manawa like, pono nā kauka e hoʻomaka i ka Sodium Thiosulfate intravenous (maʻamau 25 grams IV i hoʻokomo ʻia i ka 30 a 60 mau minuke hope loa o kēlā me kēia kau hemodialysis ʻekolu manawa i kēlā me kēia pule), hoʻoikaika i ka hemodialysis me kahi ʻauʻau dialysate haʻahaʻa-calcium, a ʻalo i ka hoʻopaʻapaʻa hohonu hohonu i ka wā o ka hoʻopaʻa ʻana o ka biopsi. ʻO ka pathergy a me ka microvascular ischemia ke hoʻonui nui ʻia nā ʻeha.

E hana i kēia i kēia manawa¶

1. **E ʻimi koke i ke komo ʻana i ka Halemaʻi a i ʻole Emergency Nephrology and Dermatology Evaluation inā loaʻa ka mea maʻi ma ka maʻi dialysis (a i ʻole ka lawe ʻana i ka warfarin) i nā ʻili ʻili ʻeha nui, nā ʻili momona subcutaneous paʻakikī, a i ʻole nā necrotic eschars ʻeleʻele. Australia, a i ʻole e nīnau i kā mākou papa kuhikuhi honua o helu pilikia. Inā loaʻa i ka mea maʻi ke kuni, ʻoʻoleʻa, hypotension, huikau, a i ʻole ka wai ʻawaʻawa mai kahi eschar ulcerated, e haʻi koke i kahi medical sepsis emergency.
2. E hoʻopaʻa a hoʻopaʻa i ka "Big Four" Pharmacological Accelerators of Calciphylaxis i ka hiki koke ʻana i ka haukapila:
3. STOP Warfarin (Vitamin K Antagonists): Kāohi ʻo Warfarin i ka gamma-carboxylation o Matrix Gla Protein (MGP), ʻo ia ka mea hoʻopaneʻe endogenous ikaika loa o ke kino o ka arteriolar medial calcification. E hoʻololi i ka mea maʻi i kahi anticoagulant waha non-vitamin-K (e like me apixaban ** ma ka hoʻoponopono ʻana i ka renal-adjusted dosing) a i ʻole heparin therapeutic ma ke kūkākūkā ʻana me ka hematology a me nephrology, a hāʻawi i ka ** Vitamin K1 (phytonadione, 10 mg waha a i ʻole IV ʻekolu manawa i kēlā me kēia pule) e hoʻihoʻi i ka MGP carboxylated ikaika.
4. HOʻOPI i nā mea hoʻopaʻa Phosphate ma muli o ka calcium a pau (PhosLo [calcium acetate], Tums [calcium carbonate]) a me nā mea hoʻohui calcium: E hoʻololi koke i nā mea hoʻopaʻa phosphate i loaʻa ʻole i ka calcium e like me sevelamer carbonate (Renvela), **lanthanum carbonate (*Fosrenolsucrot) (Velphoro)**.
5. HOʻOPI i nā Analogs All Active Vitamin D (Calcitriol, Paricalcitol, Doxercalciferol) a me High-Dose Ergocalciferol/Cholecalciferol: Hoʻonui nā agonist receptor Vitamin D i ka calcium o ka ʻōpū a me ka absorption phosphate a hoʻoulu pololei i ka calcification vascular smooth muscle. Inā he hyperparathyroidism koʻikoʻi ko ka mea maʻi (iPTH > 300 pg/mL), e hoʻololi i kahi calcimimetic (oral cinacalcet [Sensipar] a i ʻole etelcalcetide intravenous [Parsabiv]) a i ʻole e hoʻonohonoho pono i parathyroidectomy.
6. STOP Intravenous Iron Dextran/Sucrose and Subcutaneous Injections in Affected Fat Pads: Hoʻopau ka hao nui i ka ʻeha o ka hydroxyl free-radical kūloko i loko o ka ischemic dermis, a me ka hana hou ʻana ** subcutaneous insulin a i ʻole heparin injection ** i loko o ka ʻōpū panniculus a i ʻole nā ​​ʻūhā e hoʻoulu ai i ka thrombosis arteriolar kūloko. E hoʻololi i nā injections i nā wahi lean i hoʻopilikia ʻole ʻia a i ʻole ka hoʻololi ʻana i ka infusion intravenous i ka wā o ka haukapila.
7. Hoʻomaka i ka Intravenous Sodium Thiosulfate (Na2S2O3) ma 25 Grams IV ʻEkolu Manaʻo i kēlā me kēia pule (I loko o nā minuke 60 hope o kēlā me kēia Hemodialysis Session): ** ** Intravenous Sodium Thiosulfate (STS) ʻo ia ke kumu hoʻōla hoʻopakele ʻōnaehana no ka calciphylaxis acute. Hoʻokaʻawale ʻo ia i nā waihona calcium i loko o ka ** ultra-soluble calcium thiosulfate ** (ʻo ia ka 250-fold a hiki i ka 100,000-fold i ʻoi aku ka soluble i ka wai ma mua o ka calcium phosphate a i ʻole calcium oxalate a hoʻomaʻemaʻe koke ʻia ma o ka membrane hemodialysis), hana ma ke ʻano he potent free-radical antioxidant ** e hoʻihoʻi i ka endothelial sytrical nitric oxide. arteriolar vasodilation e hoemi pinepine ana i ka eha o ka ili ischemic i loko o 1 a 2 pule.
8. E kiaʻi a mālama i nā hoʻopiʻi weliweli ʻelua o ka IV Sodium Thiosulfate: High Anion Gap Metabolic Acidosis a me ka Nausea Koʻikoʻi/Hypotension:
9. Ke hoʻololi ʻia ka sodium thiosulfate e ke ake i loko o ka ** thiosulfuric acid a me nā anion sulfate **, hoʻopuka ia i kahi ** kiʻekiʻe anion gap metabolic acidosis ** (hoʻoemi pinepine i ka serum bicarbonate ma lalo o 14 a 16 mmol/L). E nānā i kahi pānaʻi metabolic maʻamau a me ka anion awāwa ma mua o kēlā me kēia kau dialysis a **e hoʻonui i ka ʻauʻau ʻauʻau hemodialysis bicarbonate ** (a i ʻole e hāʻawi i ka sodium bicarbonate waha inā ʻae ʻia ke kūlana leo).
10. ʻO ka hoʻokomo ʻana i 25 kalama o STS me ka wikiwiki loa (< 30 mau minuke) e hoʻoulu ai i ka luaʻi projectile intractable, nausea nui, a me ka hypotension intradialytic acute. E hoʻomaʻamaʻa mau me IV Ondansetron (4 a 8 mg) a i ʻole Promethazine 30 mau minuke ma mua o ka hoʻokomo ʻana, a hoʻokomo mālie iā STS ma luna o 60 mau minuke.
11. E hoʻomaikaʻi koke i ka Palapala Hemodialysis: E hoʻonui i ka pinepine dialysis a me ka lōʻihi (no ka laʻana, 4 a 5 mau manawa i kēlā me kēia pule o 4 mau hola i kēlā me kēia) e hoʻomaʻemaʻe ikaika i ka serum phosphate a me ka uremic toxins, a e hoʻololi i ka ʻauʻau dialysate i kahi konona dialysate haʻahaʻa-calcium (1.5 a i 2.0 mEq./L.) a i ʻole 0.0 mEq/L. hoʻopuehu ʻia ka calcium mai ke kahe koko o ka mea maʻi i ka wā dialysis. Inā aia ka mea maʻi ma ka peritoneal dialysis (PD) (ʻo ia ka mea e ʻoi aku ka nui o ka maʻi calciphylaxis ma muli o nā huahana hoʻohaʻahaʻa glucose peritoneal mau a me ka hoʻomaʻemaʻe ʻole o ka phosphate), e noʻonoʻo pono i ka ** hoʻololi wikiwiki i ka hemodialysis**.
12. Paʻi i ka ʻili ʻeha a pale i ka ʻokiʻoki ʻana i ka hoʻoneʻe ʻana i ka wā o ka Ischemia Active (Kaohi ʻana i ka hoʻonui ʻia ʻana o ka maʻi maʻi maʻi): ʻAʻole like me ka necrotizing fasciitis (e koi ana i ka hoʻomaʻemaʻe ākea ākea i loko o ka lumi hana), ʻoki ʻia i ka ischemic a puni, dermis calcified i ka calciphylaxis active, hoʻoulu pinepine i ka maʻi maʻi ** lua lua ole. E mālama i nā eschars maloʻo ʻeleʻele maʻemaʻe, maloʻo, a pale ʻia ke ʻole e ulu ka maʻi purulent ma lalo; i ka wā e pono ai ka wehe ʻana i ka necrotic slough no ka pale ʻana i ka maʻi maʻi, e hoʻohana i ka gentle enzymatic debridement (collagenase), hydrogel autolytic dressings, maggot debridement therapy, a i ʻole ka wehe ʻana me ka mālama ʻole ʻia o nā ʻiʻo i hoʻopaʻa ʻia me ka Hyperbaric Oxygen Therapy (HBOT) ke mālama ʻia ka calcification arteriolar.
13. ** Hāʻawi i ka Aggressive Multimodal Neuropathic a me Ischemic Pain Control (Strictly Avoiding Morphine and Meperidine in Dialysis Patients): ** ʻO ka ʻeha Calciphylaxis kekahi o nā maʻi ʻeha nui loa i ka lāʻau lapaʻau, e hui pū ana i ka infarction kiko ischemic hohonu me ka ʻeha neuropathic liʻiliʻi. Mai hoʻohana i ka morphine, codeine, a i ʻole meperidine i ka hōʻino ʻana o ka renal (ʻo kā lākou mau metabolites ʻawaʻawa morphine-6-glucuronide a me normeperidine e hōʻiliʻili i nā pae lethal e kumu ai ka myoclonus, ka hopu ʻana, a me ka hopu ʻana i ka hanu). Akā, e hoʻohana i ka intravenous a transdermal Fentanyl, Methadone, a i ʻole Buprenorphine (palekana a pau i ka dialysis me zero active renal metabolites) i hui pū ʻia me ka renal-adjusted Gabapentin (100 a 300 mg post-dialysis) a i ʻole ketamine infusions.

lāʻau hoʻoholo: manaʻo ʻia ʻo Calciphylaxis (Calcific Uremic Arteriolopathy) vs Warfarin Skin Necrosis vs Necrotizing Fasciitis¶

flowchart TD
    A["ʻO ka maʻi dialysis (HD/PD) a i ʻole ka mea hoʻohana Warfarin e hōʻike ana me ka ʻeha 10/10 ʻeha ʻili o ka ʻili + Violaceous Retiform (Net-Like) Plaques, Woody Subcutaneous Nodules, a i ʻole Stellate Necrotic Eschars ma ka ʻōpū, nā ʻūhā, nā ʻūhā, a i ʻole nā wāwae."] --> B{"KaʻAnuʻu Hana 1: Sepsis koke & Necrotizing Fasciitis Screen: Aia Aia ʻO Crepitus, ʻAi ʻAi Paʻa, Hoʻolaha wikiwiki ʻia Fascial Bullae, High Fever, a i ʻole Septic Shock?"}
    B -->|YES: Wet Gangrene / Fulminant Wound Sepsis or Necrotizing Fasciitis| C["E ho'ōla hou me ka IV Crystalloids + Broad-Spectrum IV Antibiotics (Vancomycin + Cefepime/Piperacillin-Tazobactam + Metronidazole) + Kūkākūkā ʻoki ʻoki / ʻeha no ka hoʻoheheʻe Eschar i maʻi."]
    B -->|NO: Dry Leathery Black Eschar or Intact Violaceous Plaque / Woody Subcutaneous Nodule| D["KaʻAnuʻu 2: Bedside Vascular & Medication Audit + Plain Soft-Tissue Radiographs (Mammography-Technique X-Rays) a i ʻole Bone Scintigraphy"]
    C --> D
    D --> E{"E nānā i ka manawa o ka hoʻomaka ʻana o Warfarin (Ua ulu anei ʻo Necrosis i loko o ka lā 3 a i ka lā 10 o ka hoʻomaka ʻana o Warfarin me ka ʻole o Heparin Bridge?)"}
    E -->|YES: Acute Onset Day 3 to 8 of Warfarin + Rapid Protein C Drop| F["ACUTE WARFARIN-INDUCED SKIN SKIN NECROSIS (Microvascular Venular Thrombosis): Hooki i ka Warfarin + Hāʻawi i ka IV Vitamin K + Hoʻomaka Therapeutic IV Heparin Unfractionated + Hou Frozen Plasma / Protein C Concentrate"]
    E -->|NO: Chronic Warfarin Use (> Months/Years) OR Dialysis / ESRD Patient with High Phosphate/PTH + Fine Net-Like Arteriolar Calcification on X-Ray| G["CALCIPHYLAXIS HOʻopaʻa ʻia (Calcific Uremic Arteriolopathy - CUA)"]
    G --> H["KANAWAI 1 (Hoʻopau koke i nā mea hoʻokele a pau): 1. STOP Warfarin (Hāawi i ka Vitamin K1 10 mg 3x/wk; e hoʻololi iā Apixaban inā pono ka anticoagulation); 2. STOP Calcium Phosphate Binders (E hoʻololi iā Sevelamer/Lanthanum); 3. STOP Calcitriol/Vitamin D Analogs; 4. STOP Iron & SubQ Injections in Plaques"]
    H --> I["KANAWAI 2 (E hoʻomaka i ka Calcium-Chelating & Vasodilatory Therapy): E hoʻoponopono i ka IV SODIUM THIOSULFATE (25 Grams IV ma luna o 60 mau minuke hope loa o kēlā me kēia Hemodialysis Session 3x/Week) + Premedicate me IV Ondansetron"]
    I --> J["STEP 3 (Optimize Dialysis & Parathyroid Axis): E hoʻonui i ka Hemodialysis i 4-5x / Week me LOW-CALCIUM Dialysate Bath (1.5 mEq / L); Inā iPTH > 300 pg/mL, e hoʻomaka i ka Cinacalcet / Etelcalcetide a i ʻole E hoʻonohonoho i ka Parathyroidectomy wikiwiki."]
    J --> K["KA HANA 4 (Safe Analgesia & Wound Care): E hoʻohana i ka Fentanyl, Methadone, a i ʻole Buprenorphine + Post-HD Gabapentin (NEVER Morphine / Meperidine); Hōʻalo i ka ʻokiʻoki hohonu ʻana o nā Eschars maloʻo; E noʻonoʻo i ka Hyperbaric Oxygen (HBOT) & Intralesional Sodium Thiosulfate"]

Pathophysiology: pehea ka huli ʻana o nā ʻiʻo ʻiʻo maʻemaʻe vascular i iwi a no ke aha ka ʻiʻo adipose ka pahuhopu mua¶

No nā makahiki he nui, ua manaʻo nā kauka ʻo ka calciphylaxis wale nō ka hoʻoheheʻe kemika o ka calcium a me ka phosphate i ka wā i ʻoi aku ai ka serum calcium-phosphate product (Ca x PO4) ma mua o 55 a 70 mg squared per dL squared. Ua hōʻoia ʻia e ka biology vascular o kēia wā ʻo ka calciphylaxis he hoʻololi osteogenic i hoʻopaʻa ʻia me ka cell-mediated a ukali ʻia e kahi acute thrombotic second hit:

THE TWO-HIT PATHOPHYSIOLOGY OF CALCIPHYLAXIS (CUA)
=======================================================================
[HIT 1: CHRONIC ARTERIOLAR MEDIAL CALCIFICATION & INTIMAL HYPERPLASIA]
   * Triggers in ESRD / Dialysis / Non-Uremic Warfarin Patients:
     1. Loss of Active Carboxylated Matrix Gla Protein (MGP) -> Warfarin
        or Vitamin K deficiency disables the local arteriolar shield.
     2. Loss of Systemic Fetuin-A (Negative acute-phase liver protein)
        & Inorganic Pyrophosphate (PPi) -> Fails to clear calciprotein
        particles from the bloodstream.
     3. Hyperphosphatemia + Calcium Binders + Calcitriol + High PTH ->
        Phosphate enters arteriolar Smooth Muscle Cells via Pit-1
        cotransporters, activating the bone transcription factor RUNX2
        (Cbfa1) and BMP-2 (Bone Morphogenetic Protein-2).
   * Result: Arteriolar smooth muscle cells transdifferentiate into
     OSTEOBLAST-LIKE CELLS that lay down concentric hydroxyapatite bone
     crystals in the tunica media of 40-to-600-micron subcutaneous
     arterioles, while subintimal fibrosis narrows the lumen by 80%.
                                  |
                                  v
[HIT 2: ACUTE ENDOTHELIAL THROMBOSIS & INFARCTION OF SUBCUTANEOUS FAT]
   * Local Triggers: Repetitive subcutaneous insulin/heparin injections,
     minor skin trauma (pathergy), iron overload, hypercoagulability
     (Protein C/S deficiency, lupus anticoagulant), or hypotension.
   * Result: An acute FIBRIN THROMBUS plugs the rigid, calcified
     micro-arteriole -> Complete ischemic infarction of the overlying
     adipose lobules and dermis -> Excruciating 10/10 ischemic nerve
     pain -> Violaceous retiform purpura -> Black stellate eschar.
=======================================================================

ʻO Central (Adipose-Rich) vs. Peripheral (Acral) Calciphylaxis: Nā ʻano maʻi a me ka wānana.¶

Hoʻokaʻawale nā kānaka lapaʻau i ka calciphylaxis i ʻelua mahele anatomical ʻokoʻa e lawe ana i nā hopena ola ʻokoʻa: 1. Central (Proximal / Adipose-Rich) Calciphylaxis (70% a 80% o nā hihia): Paʻi i nā wahi me ka ʻiʻo adipose subcutaneous mānoanoa, ʻo ia hoʻi ka panniculus ʻōpū, nā ʻūhā waena a me ka ʻaoʻao, nā ʻūhā, nā ʻaoʻao, a me nā umauma wahine. Ma muli o ka hoʻolako ʻia ʻana o nā lobules adipose e nā moku lōʻihi, tortuous, end-arteriolar me ka pōʻai koʻikoʻi maikaʻi ʻole a no ka mea huna nā adipocytes oʻo i nā adipokine pro-calcific (leptin, TNF-alpha, a me IL-6) e hoʻolalelale i ka hoʻoulu ʻana o ka ʻiʻo maʻemaʻe vascular RUNX2. Lawe ka calciphylaxis waena i ka kiʻekiʻe loa o ka make (60% a 80% i ka makahiki 1) no ka mea, lilo koke ka ʻeha nui o ka ʻōpū a me ka ʻūhā e nā maʻi bacteria Gram-negative enteric a me Staphylococcus aureus, e alakaʻi ana i ka maʻi bacteria make. 2. Kapilikia (20% a i ka 30% o ka ma'i): Ke ku'i nei i na wahi wīwī me ka li'ili'i o ka momona ma lalo o ke kino, e like me nā ** bipi keiki, nā ku'eku'e wāwae, nā manamana wāwae, nā manamana lima, a i kekahi manawa ka penis (penile calciphylaxis)**. Loaʻa i nā ʻeha ʻaoʻao kahi haʻahaʻa haʻahaʻa (ʻoiai ke koʻikoʻi mau) ka nui o ka make ʻana o 20% a 40%, ʻoiai ʻo ka digital a penile gangrene pono e hoʻokaʻawale pono mai nā moku nui atherosclerotic peripheral arterial maʻi (PAD) a me ka cholesterol crystal embolization. 3. Non-Uremic Calciphylaxis (NUC, 10% a 15% o nā hihia): Loaʻa i nā poʻe maʻi me ka hana maʻamau maʻamau (eGFR> 60 mL/min) i alakaʻi ʻia e ** hoʻohana warfarin maʻamau **, ** hyperparathyroidism mua **, ** nā maʻi autoimmune ma nā corticosteroids maʻamau **, a i ʻole **alcoholic sympatic cirrholic. fetuin-A a me ka Protein C/S).

ʻO ka hōʻailona ʻokoʻa ʻaoʻao: Calciphylaxis vs Warfarin-Induced Skin Necrosis vs Necrotizing Fasciitis vs Cholesterol Embolization vs Pyoderma Gangrenosum¶

Ma muli o ke kuhi hewa ʻole ʻana i ka calciphylaxis ma ke ʻano he pyoderma gangrenosum (a me ka hāʻawi ʻana i nā corticosteroids systemic kiʻekiʻe e hoʻolalelale i ka calcification a me ka sepsis) a i ʻole ke kuhi hewa ʻana he necrotizing fasciitis (a me ka hana ʻana i ka debridement excisional ākea ākea e hoʻoulu ai i ka pōʻino non-healing pathergy) hiki ke uku i ka mea maʻi i ka hoʻohālikelike ʻana i ko lākou ola:

ʻO nā pilikia hōʻailona: I ka manawa e pale aku ai i kahi Biopsy ʻili vs. Pehea e hana ai i kahi Biopsy Telescoping palekana¶

1. I ka wā e lawa ai ka hōʻike ʻana i ka maʻi maʻi + non-invasive kiʻi kiʻi (ʻaʻohe biopsy e pono ai): i ka maʻi maʻi renal hope loa ma ka dialysis e loaʻa ana i nā plaques violin violin ʻeha maʻamau, nā nodules subcutaneous lāʻau, a i ʻole nā eschars ʻeleʻele stellate ma ka ʻōpū a i ʻole nā ʻūhā. ʻO ka ʻoki ʻana i loko o kahi plaque calciphylaxis ischemic e loaʻa i kahi 30 a 50 pakeneka ka pilikia o ka hoʻoulu ʻana i ka ʻeha pathergic, ka hoʻonui ʻana i ka ʻeha hoʻōla ʻole, a me ka sepsis maʻi maʻi lua.
2. Nā ʻano ʻokoʻa kiʻi kiʻi kiʻekiʻe ʻaʻole invasive:
3. Nā Radiographs Soft-Tissue me ka hoʻohana ʻana i ka ʻenehana Mammography High-Resolution: Hōʻike i ka ** maikaʻi, lacy, arborizing (lāʻau-lāʻau a i ʻole ʻupena-like) calcifications o nā arterioles subcutaneous liʻiliʻi (< 100 a 500 micrometers)** me kahi kikoʻī kokoke i 90 pakeneka.
4. Technetium-99m (Tc-99m MDP) ʻEkolu-Phase Bone Scintigraphy: Hōʻike i ka lawe ʻana i ka radiotracer avid i loko o ka ʻā, e hoʻokahe ana i nā pā momona subcutaneous ma nā ʻūhā, ka ʻōpū, a me ka ʻāʻī (ʻike 89% a 97%).
5. Pehea e hana ai i kahi biopsy me ka palekana ke maopopo ʻole ka hōʻike ʻana (Non-Uremic Cases): Mai biopsy i ka necrotic black eschar center a pale i nā biopsies wedge excisional ākea. E hoʻohana i ka "Double-Punch" (Telescoping) Technique i alakaʻi ʻia e ka dermatopathologist ** ma ka ʻaoʻao indurated viable (he 6 mm punch tool e hiki ai i ka dermis a ukali ʻia e kahi coaxial 4 mm punch tool i holomua hohonu i loko o ka momona subcutaneous) a noi iā **Von Kossa (silver nitrate) a me Alizarin Red S calcium.

ʻO ke kaʻina hana o ka Halemai: Sodium Thiosulfate Dosing, Intralesional Rescue, Hyperbaric Oxygen, a me Novel Therapies (SNF472)¶

1. Nā Kūlana Sodium Thiosulfate Intravenous a Intralesional (Na2S2O3)¶

• Ka hoʻohana ʻana o ka hemodialysis maʻamau: Hāʻawi i ka 25 grams (100 mL o kahi 25% solution) i hoʻoheheʻe ʻia i 100 mL o 0.9% saline maʻamau i loko o ke koko i loko o ka 30 a 60 mau minuke hope o kēlā me kēia kau hemodialysis, 3 manawa i kēlā me kēia pule (no nā poʻe maʻi e kaumaha ana ma lalo o 12 kg. acidosis a me ka luaʻi).
• Ka hoʻohana ʻana i ka poʻe maʻi Calciphylaxis Non-Uremic: I nā poʻe maʻi me ka hana maʻamau maʻamau (eGFR> 60 mL/min), hāʻawi ** 12.5 i 25 grams IV i hoʻokomo ʻia ma luna o 60 mau minuke 3 a 5 mau manawa i kēlā me kēia pule** ʻoiai e nānā pono ana i ka serum bicarbonate, anion gap, calcium, a me QT interval.
• Intralesional Sodium Thiosulfate Injections: No nā pāpaʻi kūloko a i ʻole nā ​​​​mea maʻi i hoʻomanawanui ʻole i ka IV STS, hoʻokomo ka poʻe dermatologists 1 a i 3 mL o 250 mg/mL (25%) Sodium Thiosulfate i hoʻoheheʻe ʻia 1:1 me 1% Lidocaine (me ka ʻole o ka epinephrine) i loko o ka palena ikaika i hoʻokahi pule. Mai hoʻokomo i ka STS concentrated intraperitoneally (ke kumu o ka chemical peritonitis).

2. Ka hoomalu ana i ka Hyperparathyroidism lua a me ka Hyperbaric Oxygen Therapy (HBOT)¶

• Calcimimetics Over Parathyroidectomy: Inā ʻoi aku ka nui o ka hormone parathyroid (iPTH) paʻa i ka 300 pg/mL, e hoʻomaka i ka waha Cinacalcet (Sensipar, 30 a i 180 mg/lā) a i ʻole intravenous Etelcalcetide (Parsabiv, 2.5 a i 5 mg IV 3x) Ua hōʻike ka EVOLVE hoʻāʻo i ka cinacalcet e hōʻemi i ka nui o ka calciphylaxis e 69% a i 75%. Hoʻopaʻa koke ʻia ** ka parathyroidectomy kaʻi ʻana ** no ka hyperparathyroidism refractory (iPTH > 500 a i ka 1,000 pg/mL) me ka hypercalcemia mau. ʻO ka inoa ʻole IV bisphosphonates (pamidronate) a me hexasodium fytate (SNF472) ke kāohi nei i ka ulu ʻana o ka kristal hydroxyapatite i nā hihia refractory.
• Hyperbaric Oxygen Therapy (HBOT) and Safe Wound Care: No ka mea, he hypoxia ko'iko'i ka ma'i calciphylaxis (transcutaneous PO2 <20 mmHg), HBOT ma 2.0 a i 2.5 ATA no 90 mau minuke i kela la i keia la (20 a 40 mau manawa) ho'iho'i i ka oxygenation kiko a ho'oulu i ka angiogenesis. E waiho mau i nā eschars ʻeleʻele maloʻo ʻole ma ke ʻano he lole olaola; e hoʻohana i ka ** ʻaila ʻaila enzymatic collagenase, hydrogel dressings, a i ʻole sterile medical maggot therapy (Lucilia sericata)** no ka wehe ʻana i ka slough.

Nā helu ulia pōpilikia āpana a me nā protocols oihana¶

• United States and Canada: Dial 911 immediately for any dialysis patient with rapidly expanding necrotic ulcers, fever, hypotension, or intractable ischemic pain. Physicians can consult the Massachusetts General Hospital (MGH) Multidisciplinary Calciphylaxis Program and KDIGO CKD-MBD guidelines.
• United Kingdom: Dial 999 or proceed to an NHS Emergency Department / Renal Unit under UK Kidney Association (UKKA) and British Association of Dermatologists (BAD) calciphylaxis protocols.
• European Union, Australia, and Asia-Pacific: Dial 112 across the EU (European Calciphylaxis Network [EuCalNet]), 000 in Australia / 111 in New Zealand (KHA-CARI), or 119 / 995 / 999 across Asia-Pacific.

Nīnau pinepine¶

How is Calciphylaxis different from ordinary Peripheral Arterial Disease (PAD) in a patient on dialysis?¶

I ka maʻi maʻi ʻaʻaʻai maʻamau (PAD), ua hōʻemi ka cholesterol plaques i nā ʻaʻaʻa nui i kapa ʻia o nā wāwae, e hōʻeha ai i ka ʻeha bipi i ka wā e hele ai, ʻaʻohe puʻupuʻu wāwae, a me nā ʻeha ma nā manamana wāwae a i ʻole nā ​​kuʻekuʻe wāwae. I ka Calciphylaxis (Calcific Uremic Arteriolopathy), ua hāmama loa nā aʻaʻaʻa nui o nā wāwae a ikaika mau ka puʻupuʻu wāwae a me nā wāwae o ka mea maʻi. Akā, hoʻololi ka calciphylaxis i nā arteriole microscopic (ma lalo o 0.6 millimeters ka laula) i loko o nā pā momona subcutaneous i loko o ka iwi, a ukali ʻia e nā ʻōpū koko e hoʻopili i kēlā mau moku liʻiliʻi. ʻO ia ke kumu e paʻi pinepine ai ka calciphylaxis i nā wahi momona e like me ka ʻōpū, ka ʻūhā, ka ʻūhā, a me ka umauma, e hoʻoulu ai i ka ʻupena poni e like me ka ʻupena a me nā ʻili ʻeleʻele ʻeleʻele ʻoiai nā wāwae wāwae maʻamau.

Why does taking the blood thinner Warfarin (Coumadin) trigger Calciphylaxis, and why must it be stopped on Day 1?¶

No ka mālama ʻana i ka calcium a me ka phosphate i loko o ke koko mai ka lilo ʻana i iwi i loko o ko mākou mau aʻa, hana nā ʻiʻo ʻiʻo e pili ana i nā kīʻaha koko liʻiliʻi i kahi pale protein pale i kapa ʻia ʻo Matrix Gla Protein (MGP), kahi e koi ai i ka Vitamin K e hoʻololi iā ia. Hoʻopaʻa ʻo Warfarin i ka Vitamin K i loko o ke ake a i loko o nā pā kīʻaha koko, e pani ana i ka Matrix Gla Protein ma mua o 80 pakeneka. Me ka pale ʻole o ka MGP, e hoʻopaʻa koke nā arterioles liʻiliʻi i loko o ka ʻiʻo momona o ka mea maʻi maʻi dialysis i iwi palupalu, e hoʻonui ana i ka pilikia o ka calciphylaxis a hiki i ka 10-pa. ʻO ka hoʻōki koke ʻana i ka warfarin, ka hāʻawi ʻana i nā mea hoʻohui Vitamin K1 e hoʻohuli hou i ka MGP, a me ka hoʻololi ʻana i kahi mea hoʻokahe koko non-vitamin-K (e like me ka renal-dosed apixaban) pono i ka lā 1.

How is Calciphylaxis distinguished from Acute Warfarin-Induced Skin Necrosis (WISN)?¶

Acute Warfarin-Induced Skin Necrosis (WISN) strikes within the first 3 to 10 days after starting high-dose warfarin without a heparin bridge: because warfarin drops natural anticoagulant Protein C (half-life 6 hours) much faster than clotting Factor II (half-life 60 hours), the patient enters a temporary hypercoagulable state that clots dermal veins and capillaries, with zero calcium in the blood vessels. Calciphylaxis, by contrast, develops after months or years of chronic warfarin use or kidney dialysis, involves chronic bony calcification of tiny arterioles, and is treated with intravenous Sodium Thiosulfate and stopping warfarin.

How does Intravenous Sodium Thiosulfate (STS) heal Calciphylaxis ulcers and relieve pain?¶

Intravenous Sodium Thiosulfate (infused at 25 grams over the last hour of each hemodialysis session three times a week) fights calciphylaxis in three ways: it chemically chelates insoluble calcium deposits inside arteriolar walls into ultra-soluble calcium thiosulfate that washes out through the dialysis machine, acts as a potent antioxidant in starved skin, and regenerates endothelial nitric oxide to dilate surviving micro-vessels, often relieving excruciating burning pain within 7 to 14 days.

Why is aggressive surgical debridement dangerous during early active Calciphylaxis?¶

In active calciphylaxis, the surrounding purple skin and underlying fat are severely starved of blood flow because the microscopic arteriolar network is calcified and clotted. Cutting into that ischemic border with a scalpel triggers pathergy and acute microvascular thrombosis, causing the newly cut edges to die and turn black. Unless an eschar has wet pus or spreading bacterial sepsis trapped underneath it that must be drained, specialists use gentle enzymatic ointments, hydrogel dressings, sterile medical maggots, and hyperbaric oxygen therapy while Sodium Thiosulfate clears the vascular calcium.

Nā kumu a me ke alakaʻi kūhelu¶

• New England Journal of Medicine (NEJM) Clinical Practice Review (Nigwekar SU, Thadhani R, Brandenburg VM): Calciphylaxis: Pathogenesis of Calcific Uremic Arteriolopathy, Matrix Gla Protein Inhibition by Warfarin, Diagnostic Triage, and Intravenous Sodium Thiosulfate Protocol.
• Kidney Disease: Improving Global Outcomes (KDIGO): Clinical Practice Guideline Update for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
• Massachusetts General Hospital (MGH) Calciphylaxis Program and American Society of Nephrology (ASN): Interdisciplinary Management Protocol for Uremic and Non-Uremic Calciphylaxis.
• UK Kidney Association (UKKA), British Association of Dermatologists (BAD), and European Calciphylaxis Network (EuCalNet): Clinical Guidance on Calcific Uremic Arteriolopathy in Dialysis Patients.

Nā alakaʻi pili¶

• Dialysis access AV fistula life-threatening bleed and missed dialysis hyperkalemia
• Erysipelas vs necrotizing fasciitis vs stasis dermatitis: pain out of proportion, bullae, and LRINEC score triage
• Necrotizing fasciitis (flesh-eating infection) and cellulitis red flags
• Sepsis and septic shock recognition and first aid
• Nā helu pilikia ma ka ʻāina